Publication Search

Search for publications by

Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease


Initially discovered as a potent T cell proliferation factor, IL-2 was soon used for cancer immunotherapy, especially for metastatic melanoma and renal cell carcinoma; however, the severe side effects of IL-2 therapy, plus the negative role of IL-2 in maintaining of CD4+ CD25+ T regulatory cells (Tregs), has somewhat dampened enthusiasm for using IL-2 in immunotherapy. This opinion article discusses the possibility of combining IL-2 with certain anti-IL-2 antibodies for reducing the dose of IL-2 needed and preferentially stimulating effector T cells, but not Tregs, an approach that might provide an improved strategy for anticancer immunotherapy. Alternatively, complexes of IL-2 with other anti-IL-2 antibodies can selectively stimulate Tregs and could, therefore, be useful for treating autoimmune diseases.

Type Journal
ISBN 1744-7682 (Electronic)
Authors Boyman, O.;Surh, C. D.;Sprent, J. :
Garvan Authors Prof Jonathan Sprent
Published Date 2006-01-01 00:00:00
Published Volume 6
Published Issue 12
Published Pages 1323-31
Status Published In-print
OpenAccess Link Boyman EOBT.pdf